175 related articles for article (PubMed ID: 12747780)
21. Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Staedler D; Chapuis-Bernasconi C; Dehmlow H; Fischer H; Juillerat-Jeanneret L; Aebi JD
J Med Chem; 2012 Jun; 55(11):4990-5002. PubMed ID: 22533316
[TBL] [Abstract][Full Text] [Related]
22. Rationally designed inhibitors as tools for comparing the mechanism of squalene-hopene cyclase with oxidosqualene cyclase.
Viola F; Ceruti M; Cattel L; Milla P; Poralla K; Balliano G
Lipids; 2000 Mar; 35(3):297-303. PubMed ID: 10783007
[TBL] [Abstract][Full Text] [Related]
23. Arylpiperidines as a new class of oxidosqualene cyclase inhibitors.
Keller M; Wolfgardt A; Müller C; Wilcken R; Böckler FM; Oliaro-Bosso S; Ferrante T; Balliano G; Bracher F
Eur J Med Chem; 2016 Feb; 109():13-22. PubMed ID: 26745812
[TBL] [Abstract][Full Text] [Related]
24. Induction of CYP3A by 2,3-oxidosqualene:lanosterol cyclase inhibitors is mediated by an endogenous squalene metabolite in primary cultured rat hepatocytes.
Shenoy SD; Spencer TA; Mercer-Haines NA; Abdolalipour M; Wurster WL; Runge-Morris M; Kocarek TA
Mol Pharmacol; 2004 May; 65(5):1302-12. PubMed ID: 15102959
[TBL] [Abstract][Full Text] [Related]
25. Lord of the rings--the mechanism for oxidosqualene:lanosterol cyclase becomes crystal clear.
Huff MW; Telford DE
Trends Pharmacol Sci; 2005 Jul; 26(7):335-40. PubMed ID: 15951028
[TBL] [Abstract][Full Text] [Related]
26. The monotopic membrane protein human oxidosqualene cyclase is active as monomer.
Ruf A; Müller F; D'Arcy B; Stihle M; Kusznir E; Handschin C; Morand OH; Thoma R
Biochem Biophys Res Commun; 2004 Mar; 315(2):247-54. PubMed ID: 14766201
[TBL] [Abstract][Full Text] [Related]
27. Structure activity relationships of new inhibitors of mammalian 2,3-oxidosqualene cyclase designed from isoquinoline derivatives.
Binet J; Thomas D; Benmbarek A; de FD; Renaut P
Chem Pharm Bull (Tokyo); 2002 Mar; 50(3):316-29. PubMed ID: 11911193
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and biological evaluation of new (2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-ol ethers as inhibitors of human and Trypanosoma cruzi oxidosqualene cyclase.
Galli U; Oliaro-Bosso S; Taramino S; Venegoni S; Pastore E; Tron GC; Balliano G; Viola F; Sorba G
Bioorg Med Chem Lett; 2007 Jan; 17(1):220-4. PubMed ID: 17027267
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic insights into oxidosqualene cyclizations through homology modeling.
Schulz-Gasch T; Stahl M
J Comput Chem; 2003 Apr; 24(6):741-53. PubMed ID: 12666166
[TBL] [Abstract][Full Text] [Related]
30. Deletion of the Gly600 residue of Alicyclobacillus acidocaldarius squalene cyclase alters the substrate specificity into that of the eukaryotic-type cyclase specific to (3S)-2,3-oxidosqualene.
Hoshino T; Shimizu K; Sato T
Angew Chem Int Ed Engl; 2004 Dec; 43(48):6700-3. PubMed ID: 15593147
[No Abstract] [Full Text] [Related]
31. Access of the substrate to the active site of squalene and oxidosqualene cyclases: comparative inhibition, site-directed mutagenesis and homology-modelling studies.
Oliaro-Bosso S; Schulz-Gasch T; Taramino S; Scaldaferri M; Viola F; Balliano G
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1202-5. PubMed ID: 16246081
[TBL] [Abstract][Full Text] [Related]
32. Design strategies of oxidosqualene cyclase inhibitors: Targeting the sterol biosynthetic pathway.
Rabelo VW; Romeiro NC; Abreu PA
J Steroid Biochem Mol Biol; 2017 Jul; 171():305-317. PubMed ID: 28479228
[TBL] [Abstract][Full Text] [Related]
33. Structure and function of a squalene cyclase.
Wendt KU; Poralla K; Schulz GE
Science; 1997 Sep; 277(5333):1811-5. PubMed ID: 9295270
[TBL] [Abstract][Full Text] [Related]
34. Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis approach.
Oliaro-Bosso S; Schulz-Gasch T; Balliano G; Viola F
Chembiochem; 2005 Dec; 6(12):2221-8. PubMed ID: 16235265
[TBL] [Abstract][Full Text] [Related]
35. 1-methylidenesqualene and 25-methylidenesqualene as active-site probes for bacterial squalene:hopene cyclase.
Tanaka H; Noguchi H; Abe I
Org Lett; 2004 Mar; 6(5):803-6. PubMed ID: 14986979
[TBL] [Abstract][Full Text] [Related]
36. Oxidosqualene cyclase inhibitors as antimicrobial agents.
Hinshaw JC; Suh DY; Garnier P; Buckner FS; Eastman RT; Matsuda SP; Joubert BM; Coppens I; Joiner KA; Merali S; Nash TE; Prestwich GD
J Med Chem; 2003 Sep; 46(20):4240-3. PubMed ID: 13678402
[TBL] [Abstract][Full Text] [Related]
37. Stereospecific syntheses of trans-vinyldioxidosqualene and 3-hydroxysulfide derivatives, as potent and time-dependent 2,3-oxidosqualene cyclase inhibitors.
Viola F; Balliano G; Milla P; Cattel L; Rocco F; Ceruti M
Bioorg Med Chem; 2000 Jan; 8(1):223-32. PubMed ID: 10968281
[TBL] [Abstract][Full Text] [Related]
38. Site-directed mutagenesis of squalene-hopene cyclase: altered substrate specificity and product distribution.
Dang T; Prestwich GD
Chem Biol; 2000 Aug; 7(8):643-9. PubMed ID: 11048954
[TBL] [Abstract][Full Text] [Related]
39. Influence of conformation on GRIND-based three-dimensional quantitative structure-activity relationship (3D-QSAR).
Caron G; Ermondi G
J Med Chem; 2007 Oct; 50(20):5039-42. PubMed ID: 17760433
[TBL] [Abstract][Full Text] [Related]
40. A novel series of 4-piperidinopyridine and 4-piperidinopyrimidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase.
Brown GR; Hollinshead DM; Stokes ES; Waterson D; Clarke DS; Foubister AJ; Glossop SC; McTaggart F; Mirrlees DJ; Smith GJ; Wood R
J Med Chem; 2000 Dec; 43(26):4964-72. PubMed ID: 11150166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
